Personalized,Cancer,Treatment,2, Impact,of,Emerging,Science,on, Treatment,Paradigms! UICC,World,Cancer,Congress,, August,2012,
|
|
- Patrick Paul
- 5 years ago
- Views:
Transcription
1 Personalized,Cancer,Treatment,2, Impact,of,Emerging,Science,on, Treatment,Paradigms! UICC,World,Cancer,Congress,, August,2012,! Elizabeth*A.*Eisenhauer*MD*FRCPC* Department*of*Oncology,*Queen s*university* *Kingston,*Canada*
2 Outline! What!is!personalized!cancer!treatment?! Examples!of!successes! Challenges!to!be!addressed! And!poten<al!solu<ons!
3 One!Concept!!Many!Names! Personalized!Medicine!!!=!Stra<fied!Medicine!!!!!=!Precision!Medicine!!!!!!=!Tailored!Medicine!
4 Personalized!Medicine!!! One!concept,!a!mul<tude!of! meanings!and!perspec<ves! Pa$ent:! I!want!my!doctor!to!know!about! my!life,!to!understand!me!and!my! family!and!to!help!me!reach, decisions,that,are,best,for,me.,, I!did!not!want!to!lose!my!hair!on! treatment!so!we!found!an!op<on! for!me!that!would!spare!my!hair.! Clinician:! Which!pa<ent!or!disease! features!will!alter,my, approach,to!preven<on,! screening,!or!treatment?!!
5 Personalized!Medicine!!! Scien$st:! One!concept,!a!mul<tude!of! Each!pa<ent s!cancer!has!gene<c! changes!and!each!pa<ent!has! meanings!and!perspec<ves! genomic!varia<ons!that!make! them!unique.!we!are!looking!for! those!changes!that!will!allow!the! right!pa<ent!to!receive!the!right! treatments!matched!to!their! genedc,fingerprint.,
6 Today s!topic:!! Matching!specific!muta<ons!in!a!pa<ent s! cancer!with!targeted!therapy(ies)!
7 Personalized!Medicine!Examples!! Already*in*Use*in*Cancer*Medicine* Safe!chemotherapy!dosing! Carbopla<n!dosed!based!on!individual!GFR.! Breast!cancer!screening!in!BRCA!mut.!carriers:!! MRI!based;!prophylac<c!surgery! Prognos<c!gene!signatures! Guide!who!does!NOT!need!treatment! Individualized!planning!for!radia<on!treatment! Stra<fica<on!of!tumours!based!on!molecular! findings!that!predict!treatment!benefit!thus! allow!treatment!selec<on!
8 Examples!! Personalized!! New!Cancer!Therapies!
9 Example*1:! Breast!cancer:!! Inhibi<ng!HER2!
10 Newly!diagnosed! breast!cancer!pts! have!cancer! analysed!markers:! Estrogen!and! progesterone! receptors! HER2!protein! Pa<ents!with!HER2!+! cancer!treated!with! trastuzumab:! Breast!Cancer! 7%! improvement! at!4!years!
11 Example*2:! Malignant!Melanoma:!! Inhibi<ng!Mutated!BRAF!
12 Here we report BRAF somatic missense mutations in 66% of malignant melanomas June*2002:* BRAF!muta<ons!in! ~2/3!melanoma! >90%!are!V600E! Development!of! inhibitors!of! mutated!braf!next! logical!step!
13 Targe<ng!MUTANT!BRAF!protein! Agent!designed!to!inhibit!mutated!variant!of!target!!!select! for!pa<ents!having!tumours!with!mutated!target.! Vemurafenib! (PLX!4032)!!
14 Metasta<c!Melanoma:!! Drama<c!improvement! in!scans!within!2!weeks! of!targeted!braf! inhibitor!therapy!
15 Chapman!PB,!et!al!NEJM!2011!
16 Over!past!decade!!Several!other!examples!of! successful!molecular!targeted!therapy! Disease, GeneDc,abnormality/ Test, Drug,, (examples), Survival, impact, Breast!cancer! HER2!amplifica<on! trastuzumab!! years! Melanoma! BRAF!V600E!muta<on! vemurafenib! months! GI!Stromal! Tumour! Chronic!Myeloid! Leukemia! clkit!muta<on! ima<nib!! years! bcrlabl!transloca<on! ima<nib!! years! Colorectal!cancer!! Kras!wild!type! cetuximab! months! Lung!cancer!! EGFR!muta<on! gefi<nib! months! ALKlEML4! transloca<on! crizo<nib! months!
17 Over!same!decade.! Powerful!next!genera<on!genomic!sequencing! technologies!have!become!available! QUESTION:! Could!we!simply!sequence!an!individual! pa<ent s!tumour!to!discover!all!abnormali<es!to! design! cocktail!of!therapeu<cs?!
18 The!proposed!new!! personalized!paradigm! New,cancer,diagnosis, Malignant,Dssue, sent,for,genedc,tests, Specific,therapies,as,dictated,by,test,results,added,, to,standard,of,care,(surgery,,radiadon,,chemo), Disease,relapses, Malignant,Dssue, sent,for,genedc,tests, Specific,therapies,as,dictated,by,test,results,
19 High!expecta<ons!within!scien<fic!community! and!public!of!transforma<on!in!cancer!care!and! beper!outcomes!coming!soon!
20 How!realis<c!is!this?! What!challenges!must!be!overcome! before!this!is!a!reality!for!all!cancer! pa<ents?!! Technology!and!tes<ng! Complex!muta<onal!nature!of!cancers! Drugs! Costs!
21 Challenges!!! Muta<on/Gene<c!Tes<ng! How!will!SYSTEM!address!issues:! When,to!test! Access!to!tests/technology! Quality!controlled!tes<ng! Standard!test!interpretaDon,
22 When!to!test?! At!diagnosis?!At!relapse?!In!all!pa<ents?! Paradigms!will!need!to!be!disease!specific!as! new!treatments!are!relevant!in!different! diseases!at!different!<mes.! Evidence!base!upon!which!to!build! recommenda<ons!
23 Which!Tests?! Oneltestlatlal<me! * versus*! Mul<plex!tes<ng! * versus*! Genome!sequencing!
24 Which!Tests?! One2test2at2a2Dme, * versus*! Mul<plex!tes<ng! * Most!similar!to!tes<ng!done!in!pathology!labs!now.!! versus* Quality!control!(QC)!easily!achievable!! Cost!per!test!high! Genome!sequencing! Limited!to!exact!muta<on!in!test!
25 Which!Tests?! Oneltestlatlal<me! * versus*! MulDplex,tesDng, * More!efficient!l!!cost!per!muta<on!lower;!<ssue!per! versus* muta<on!lower!! QC!more!challenging!but!achievable!!regional!network!of! Genome!sequencing! labs?! Results!limited!to!muta<ons!in!panel!
26 Which!Tests!and!When?! Many!muta<ons!will!be!found!!!interpreta<on!becomes! more!of!an!issue! QC!/<meliness!issues?! Oneltestlatlal<me! Will!need!specialized!network!of!labs! * Data!storage!and!analysis!major!issues!esp.!for!clinical! applica<ons! versus* EXPENSIVE!!though!costs!falling!! Mul<plex!tes<ng! * versus*! Genome,sequencing,
27
28 Addressing!Challenges! Whole!exome!sequencing,!although!important! for!discovery!research,!is!not!going!to!be!a! rou<ne!test!for!treatment!decisions!any<me! soon.! More!likely!scenario:!tes<ng!for!specific! muta<ons!in!mul<plex!panel!l!perhaps! bundled!by!disease!type!in!designated! networks!of!laboratories!! Several!countries!are!undertaking!ini<a<ves! aimed!at!implemen<ng!
29 Ini<a<ves!to!Enable!Laboratory! Implementa<on!!Cancer!Research!UK! Stra<fied!Medicine!Programme! Aims!to!establish!the!founda<ons!of!a!na$onal! service!of!gene$c!tes$ng! Phase!I!l!!July!2011l2013:! Pilot!study!!in!7!exis<ng!Experimental!Medicine!Centres! Will!recruit!7,!000!pa<ents!with!breast,!bowel,!lung,! prostate,!ovary,!melanoma! Tissue!samples!sent!to! technology!hubs!to!extract! DNA,!test!for!a!panel!of!specific!gene<c!abnormali<es!!
30 Ini<a<ves!to!Enable!Implementa<on!!! Ins<tut!Na<onal!du!Cancer!!(France)!! 28lcenter!personalized!medicine!tes<ng! network! INCa!funds!emerging!tests!while!they!progress! towards!standard!of!care,!thereby!facilita<ng! early!access.!! Network!focusses!on!single!tests:!currently! offers!egfr,!klras,!blraf,!eml4lalk,!and! HERl2!tes<ng.!
31 Challenges!!! Genome!sequencing:! Which!muta<ons!are!important?! Cancers!are!complex!and!heterogeneous!with! mul<ple!muta<ons,!copy!number!changes!
32 Nature,!June!2012! 100!primary!breast!cancers! 21,416!protein!coding!genes!and!1,664!microRNAs!sequenced! 7,!241!soma<c!point!muta<ons!l!!4,737!missense,!422!nonsense! Driver,mutaDons,in,at,least,40,cancer,genes, 73,different,combinaDons,of,mutated,cancer,genes,
33 Challenges!!!! Furthermore! Tumours!are!constantly!evolving!! Within!an!individual s!cancer,!molecular! changes!are!not!sta<c!geographically!or!over! <me.!
34
35
36 RESISTANCE!to!treatment!can!develop:! BRAF!inhibitor!response!at!2!weeks!l!!and! progression!at!6!months!!
37 Challenges!!! Complexity!and!Malignant! Evolu<on! Some!argue!that!this!makes!the!no<on!of! undertaking!personalized!medicine!an! unobtainable!dream!!l!!constant!race!against! <me!where!the!more!we!run!the!more!we!will! stand!s<ll.!
38 Addressing!the!Challenges?! Not!all!muta<ons!are!relevant!or!important!!! need!more!research!into!the!biological! importance!of!(commonly)!iden<fied!muta<ons! that!are!discovery!in!sequencing!to!know!which! are!really! driving!cancer.!! Target,the,mutaDons,in,the, trunk,of,the, phylogenedc,tree,
39 Challenge!!Too!Few!Good!Drugs! Many!targeted!agents!have!only!modest!an<l cancer!ac<vity!!and! Most!have!toxici<es!related!to!effects!on! normal!<ssue!
40 Modest!effect!of!targeted!drugs?!! Most!new!drugs!tested!first!in!advanced!/! metasta<c!cancer.! While!many!can!induce!tumour!shrinkage!this! may!be!short!lived!and!effect!on!survival!is! limited!(with!some!notable!excep<ons)!! The!more!important!test!of!their!impact!is!in! the!adjuvant!sevng!!where!truly!ac<ve!drugs! should!increase!long!term!survival/cure!rates!
41 What,are,the,Adjuvant,Results,of, FDA,Approved,Targeted,Agents,
42 Target!Agent! Approved!advanced! Adjuvant!?!status?! disease!indica$on!! mtor! everolimus! Renal! 1!trial!ongoing! Panc.!Neuroend.!?! temsirolimus! Renal!?! VEGF/! bevacizumab! Colorectal! 2,trials,negaDve,(CO28,,AVANT)! VEGFR! Lung! 1!trial!not!reported!(E1505)!! Renal! l! Brain! 2!trials!in!GBMl!not!reported! Breast! Several!trials!not!reported! suni<nib! Renal! 3!trials!l!ongoing! Panc.!Neuroend.!?! GIST!?! sorafenib! Renal! 3!trials!l!ongoing! Hepatocellular! 1!trial!not!reported! pazopanib! Renal! 1!Trial!l!ongoing! vandetanib! Thyroid!?! axi<nib! Renal!?!
43 Target! Agent! Approved!advanced! Adjuvant!?!status?! disease!indica$on!! HER2! trastuzumab! Breast! Trials,posiDve,for,RFS/OS! Gastric!?! lapa<nib! Breast! 1!trial!(ALTTO)!not!reported! EGFR!! panitumumab! Colorectal! 1!trial!in!rectal!ongoing! cetuximab! Colorectal!!! 1,trial,,negaDve,in,RAS,WT;, worse!outcome!in!ras!mut* Head!and!Neck! 1!trial!(RTOG!0920)!ongoing! erlo<nib! NSCLC!!! 1!trial!!(RADIANT)!not!reported! 2!trials!ongoing! Pancreas! 2!trials!ongoing! gefi<nib!! NSCLC! 2,trials,negaDve,(BR19,,S0023), (gefi$nib!arm!?!worse!outcome)! 1!trial!recrui<ng!in!EGFR!mut! Kit! ima<nib! GIST!! Trials,posiDve,for,RFS,&,OS! BRAF! vemurafenib! Melanoma! ongoing! EML4l ALK! crizo<nib! NSCLC!?!
44 Toxicity!!may!limit!dosing!(and!efficacy?)! Many!targeted!drugs!are!designed!to!inhibit!normal! variant!of!the!molecule,!causing!normal!<ssue!toxicity! This!also!has!limited!our!ability!to!combine!targeted! agents.! Skin!rash!! EGFR!inhibitors! Hypertension!! angiogenesis! inhibitors!
45 This!is!the!most!important!challenge! No!maGer!how!good!we!are!at!defining!the! molecular!changes!in!a!pa$ents!tumours!! there!will!be!no!real!impact!on!cancer!control!if! the!drugs!available!to!treat!these!changes!have! limited!ac$vity.!
46 Solu<ons?! We!would!all!like!the!answer!to!this!one!! Some!sugges<ons?! Beper!choice!of!molecular!targets!!develop!drugs! that!target!abnormal!variants!of!key!proteins!! not!the!normal!ones! Set!bar!higher!for!performance!in!drugs!selected! for!tes<ng!test:!!! e.g.!those!that!inhibit!the! abnormal!target!by!>!95%! (even!>99%)!at!safe!doses!!instead!of!the!40l80%! inhibi<on!most!drugs!today!are!achieving!!
47 Effect!of!oral!PI3k!inhibitor!BKM120!on!pS6! levels!in!skin!biopsies,!by!dose!cohort.!! BKM120!>80!mg:! 40%,2,85%,decrease!in!pS6! levels!compared!to!baseline! 2012 by American Society of Clinical Oncology Bendell J C et al. JCO 2012;30:
48 AromaDzaDon,rate, inhibited,by,>,98.9%, at,2.5,mg,letrozole.,
49 Challenge!!Costs!vs.!Benefits! Is*vision*personalized*medicine*affordable*within* a*public*funded*system?* With!today s!technologies!and!drugs!!!no! New!cancer!drugs!are!very!expensive!and,!with! some!excep<ons,!have!not!had!drama<c!benefits! Tes<ng!is!expensive! May!!be!cost!savings!IF!(inexpensive)!test!to! restrict!popula<on!is!iden<fied!after!a!drug!is! already!being!used!in!prac<ce! BUT!for!drugs!marketed!with!test!developed!in! parallel!!costs!are!high!
50 Tipping!the!balance!in!favour!of!affordability?! Some!thoughts!of!a!nonleconomist! Gene<c!tes<ng!of!tumours:! Coordinated!lab!network;!Beper!(cheaper)!mul<plex!tests! Evidence!based!algorithms!of!when/who!to!test!! Drug!Treatments:! New!genera<on!of!treatment(s)!should!offer!gains!in! meaningful!outcomes!!that!are!sustained!(i.e.!survival)! Drug!pricing!! needs!discussion!across!borders price!should!reflect! meaningful!benefits!achieved.! But,we,are,a,long,way,from,global,access,to,, genome,based,personalized,cancer,treatment,
51 Summary:!Personalized!Medicine! Not!really!a!new!paradigm! New,breast,cancer,diagnosis, Malignant,Dssue, sent,for,her2,tests, Trastuzumab,treatment,HER2+,ajer, to,standard,of,care,(surgery,,radiadon,,chemo), Disease,relapses, Malignant,may,be, re2evaluated, Specific,therapies,as,dictated,by,test,results,
52 Many!Challenges!before!!Full! Vision!of! Personalized!Therapy!can!be!Realized! Cancer!genome!sequencing!of!all!pa<ents!to! determine!which!drugs!they!will!receive!is!far!in!future! but!progress!made!towards!this!in!past!decade.!! Several!important!challenges!remain:! Clear!algorithms!for!tes<ng!and!decision!points! Decisions!on!gene<c!tes<ng/plazorms/data!storage! Beper/more!affordable!drugs!targe<ng!mutated!variants! Encourage!real!world!evalua$on!!of!new! technologies/drugs!in!cancer!care!system!!fund! approaches!to!enhance!efficiencies!and!reduce!costs!
53 Thank!You!for!Your!Apen<on!!
I. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationImplementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges
Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Frédérique Nowak - 21 october 2015 "Putting Science into Standards event:
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationCDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More informationNew Developments in Cancer Treatment. Ian Rabinowitz MD
New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis
More informationA 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationUniversity of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationImaging Cancer Treatment Complications in the Chest
Imaging Cancer Treatment Complications in the Chest Michelle S. Ginsberg, MD Objectives Imaging Cancer Treatment Complications in the Chest To understand the mechanisms of action of different classes of
More informationImmunotherapy and Targeted Therapies: The new face of cancer treatment
Immunotherapy and Targeted Therapies: The new face of cancer treatment Abdulazeez Salawu MBBS, MSc, PhD, MRCP Academic Clinical Lecturer Weston Park Hospital, Sheffield Novel Systemic Anti-cancer Therapies
More informationCombining Stroma-Targeted Therapies with Radiation to Prevent Resistance
Combining Stroma-Targeted Therapies with Radiation to Prevent Resistance Dan G. Duda, DMD, PhD Harvard Medical School New Cancer Targets NCT Conference Sesptember 23, 2013 Conflicts of Interest None Tumor
More informationEuropean consortium study on the availability of anti-neoplastic medicines
European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department
More informationCUP: Treatment by molecular profiling
CUP: Treatment by molecular profiling George Pentheroudakis Professor of Oncology Medical School, University of Ioannina Greece Chair, ESMO Guidelines September 2018 Enterprise Interest No disclosures.
More informationIndividualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
More informationChallenges in Personalized Cancer Medicine. Chris&an Peschel 3. Medizinische Klinik Klinikum rechts der Isar der Technischen Universität München
Challenges in Personalized Cancer Medicine Chris&an Peschel 3. Medizinische Klinik Klinikum rechts der Isar der Technischen Universität München Personalized Cancer Medicine Expecta6ons and Reality Expecta6ons
More informationPatient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
More informationNew Drug development and Personalized Therapy in The Era of Molecular Medicine
New Drug development and Personalized Therapy in The Era of Molecular Medicine Ramesh K. Ramanathan MD Virginia G. Piper Cancer Center Translational Genomics Research Institute Scottsdale, AZ Clinical
More information17/01/2017. Use of kinase inhibitors in oncology practice. Multikinase inhibitors. Sunitinib (Sutent )targets. Many more sunitinib kinase targets (42)
Multikinase inhibitors Use of kinase inhibitors in oncology practice Prof Jacques De Grève, UZ Brussel Inhibit multiple intracellular and cell surface kinases Tyrosine or serine-threonine kinases Multitargeting
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationASSOCIAZIONE CULTURALE GIUSEPPE DOSSETTI THE PARADIGM OF PERSONALIZED THERAPY IN ONCOLOGY
ASSOCIAZIONE CULTURALE GIUSEPPE DOSSETTI THE PARADIGM OF PERSONALIZED THERAPY IN ONCOLOGY Giampietro Gasparini Oncology - San Filippo Neri Hospital Rome, Italy Roma, 26 October 2011 www.professorgasparini.com
More informationSelecting the right patients for the right trials.
Selecting the right patients for the right trials. Paul Waring Professor of Pathology University of Melbourne June 21, 2011 RCPA Genetics short course Drug development challenges. Current model of drug
More informationDRUGS DEVELOPMENT METHODOLOGY
DRUGS DEVELOPMENT METHODOLOGY The unavoidable break with the past Prepared by: Kotecki N, Awada A, Adjei A, Argiles G, Arnold D, Blay JY, Collignon O, Dittrich C, Janku F, Lacombe D, Penel N, Tabernero
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationPractice of Medicine-1 Ovarian Cancer Clinical Correlation
Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by
More informationGenomics Up Close And Personal: What Are The Implications For Cancer Nursing? Candy Cooley Head of Education
Genomics Up Close And Personal: What Are The Implications For Cancer Nursing? Candy Cooley Head of Education Aims of this session Understand how genomic information will change your clinical practice Remind
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationA Day in the Life of a Breast Cancer Doctor: Integrating Omics to Optimize Patient Outcomes. March 17-18, 2015 New York, NY
A Day in the Life of a Breast Cancer Doctor: Integrating Omics to Optimize Patient Outcomes March 17-18, 2015 New York, NY A Day in the Life of a Breast Cancer Doctor: Integrating Omics to Optimize Patient
More informationClinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
More informationTHE TWENTY LESSONS LEARNT FROM THE DEVELOPMENT OF MOLECULAR- TARGETED THERAPIES. Prepared by: N. Kotecki, MD G. Argilés, MD, PhD A.
THE TWENTY LESSONS LEARNT FROM THE DEVELOPMENT OF MOLECULAR- TARGETED THERAPIES Prepared by: N. Kotecki, MD G. Argilés, MD, PhD A. Awada, MD, PhD DISCLOSURES Nuria Kotecki has reported no conflicts of
More informationMolecular portraits/landscape of lung cancer in France
Molecular portraits/landscape of lung cancer in France Jean-Charles SORIA Frédérique NOWAK Fabien CALVO U981 2 Disclosure Slide Member of the SAB of the french NCI (INCA). Appointed by the Ministry of
More informationRare Cancers. Andrew J. Wagner, MD, PhD Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Sarcoma Patient Symposium October 15, 2017
Rare Cancers Andrew J. Wagner, MD, PhD Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Sarcoma Patient Symposium October 15, 2017 Why should we care about Rare Cancers? Raise your hand
More informationCell, Volume 141. Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger
Cell, Volume 141 Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger Figure S1. RTK Mutations in Diseases Locations of gain-of-function (green arrows)
More informationInternational Course on Theranostics and Molecular Radiotherapy ImmunoPET in Breast Cancer
International Course on Theranostics and Molecular Radiotherapy ImmunoPET in Breast Cancer Geraldine Gebhart Jules Bordet Institute 5/10/2017 PLAN OF THE TALK Increasing role of antibodies in anti-cancer
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More information1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?
1. The metastatic cascade 3. Pathologic features of metastasis 4. Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of Paget s disease of the nipple (intraductal
More informationCLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12
Page: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationShould novel molecular therapies replace old knowledge of clinical tumor biology?
Should novel molecular therapies replace old knowledge of clinical tumor biology? Danai Daliani, M.D. Director, 1 st Oncology Clinic Euroclinic of Athens Cancer Treatments Localized disease Surgery XRT
More informationDrug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist
Drug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist Moderator: S. Terence Dunn, Ph.D. Associate Professor, Pathology Director, Molecular Pathology Laboratory University
More informationPhase II Cancer Trials: When and How
Phase II Cancer Trials: When and How Course for New Investigators August 9-12, 2011 Learning Objectives At the end of the session the participant should be able to Define the objectives of screening vs.
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationPhase II Cancer Trials: When and How
Phase II Cancer Trials: When and How Course for New Investigators August 21-23, 2013 Acknowledgment Elizabeth Eisenhauer for some slides! Learning Objectives At the end of the session the participant should
More informationValida5on of a Microsatellite Instability Assay by NGS
Valida5on of a Microsatellite Instability Assay by NGS Mark R. Miglarese, Ph.D. VP R&D 1 Caris Life Sciences 230,000+ tests performed in 2016 Headquarters: Irving, Texas Laboratory: Phoenix, Arizona 66,000
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationIs there a Cookbook for Oncology Clinical Trials?
Masterclass for Masters See beyond : An Oncology Brainstorm Ghent, 16th of September 2016 Is there a Cookbook for Oncology Clinical Trials? Dimitrios Zardavas MD Associate Scientific Director, Breast International
More informationTDM of Targeted Therapies in Oncology: where do we stand? Dr. Joseph Ciccolini SMARTc - Pharmacokinetics Unit AMU/APHM Inserm U1068 CRCM
TDM of Targeted Therapies in Oncology: where do we stand? Dr. Joseph Ciccolini SMARTc - Pharmacokinetics Unit AMU/APHM Inserm U1068 CRCM Disclosures Roche Merck Serono Novartis How to improve clinical
More informationStrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient
StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in
More informationWorking Formulary January 2013 Oncology Chemotherapy Regimens
Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationGASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 2: ISSUE 23: December 16, 2010 Coming soon: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study
More informationNSCLC 2 nd and further line therapies. Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute
NSCLC 2 nd and further line therapies Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute e.smit@nki.nl ESMO Guidelines 2016: Treatment of Stage IV nonsquamous NSCLC at progression
More informationDr C K Kwan. Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK
HA Convention 2013 Dr C K Kwan MBChB, FRCR, FHKCR, FHKAM, MPM, CPI, MAppMgt(Hlth) Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK To personalize cancer
More informationOpening Address: A Quick Survey Thinking 25 Years Backwards & Forwards
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationMultiple Receptor Tyrosine Kinase Inhibitors
PHARMACY POLICY 5.01.534 Multiple Receptor Tyrosine Kinase Inhibitors Effective Date: Nov. 1, 2018 Last Revised: Oct. 9, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.517 Use of Vascular Endothelial
More information2019 QPP Measures for Pathologists Diana Cardona, MD, FCAP February 12, 2019
2019 QPP Measures for Pathologists Diana Cardona, MD, FCAP February 12, 2019 Welcome Diana Cardona, MD, FCAP Chair, Measures & Performance Assessment Subcommittee Today Overview of MIPS 2019 Quality Category
More informationTumor monitoring in a drop of blood.
Tumor monitoring in a drop of blood. PRECISION MEDICINE STARTS WITH A FINGER STICK. circulogene.com Circulogene Theranostics solution to liquid biopsy. Novel cell-free DNA enrichment method for high quantity
More informationOral mucositis associated with targeted therapy and immunotherapy: what s old is new again
Oral mucositis associated with targeted therapy and immunotherapy: what s old is new again Nathaniel Treister, DMD, DMSc Associate Surgeon Brigham and Women s Hospital Associate Professor Harvard School
More informationGreg Cook Associate Director, Market Access, Bristol-Myers Squibb Australia
NICE PBAC PBS CADTH Access Challenges Greg Cook Associate Director, Market Access, Bristol-Myers Squibb Australia Disclaimer: The views expressed in this presenta5on are those of the author not his employer
More informationThe Clinical Research E-News
Volume 3: ISSUE 2: January 26, 2011 The Clinical Research E-News Now Open: E2208, Randomized Phase II Study of Paclitaxel With or Without the Anti- IGF-IR mab Cixutumumab (IMC-A12) as Second Line Treatment
More information1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications
Metastasis 1.The metastatic cascade 2.Pathologic features of metastasis 3.Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of bone Paget s disease of the
More informationTreatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward Maha Hussain, MD, FACP Professor of Medicine & Urology Co-Leader Prostate/GU Oncology Program Associate Director for Clinical
More informationOnly In Few Cases Have Subgroups Been Defined in Advance With Formal Analysis
Backups Session 4 Only In Few Cases Have Subgroups Been Defined in Advance With Formal Analysis Imatinib and Kit + GIST (prospective, preapproval) Dasatinib and PH + ALL (prospective, preapproval) Maraviroc
More informationState of the art for radiotherapy of SCCHN
State of the art for radiotherapy of SCCHN Less side effects Cured More organ & function preservation Head & neck cancer = 42 000 new cases / year in Europe Not cured Local failure Distant failure More
More informationThe new Leeds Solid Tumour Molecular Oncology Diagnostics Service. Paul Roberts, Genetics, Leeds
The new Leeds Solid Tumour Molecular Oncology Diagnostics Service Paul Roberts, Genetics, Leeds Molecular Oncology services pre-2013 DNA lab Germline cancer Cytogenetics lab FISH, cell culture, molecular
More informationNCI Community Cancer Centers Program
NCI Community Cancer Centers Program BIOSPECIMENS SURVIVORSHIP Andrew L. Salner, MD FACR Director, Helen & Harry Gray Cancer Center Hartford Hospital Hartford, CT Hartford Hospital 865 bed community and
More informationOverview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade
Overview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade David L. Rimm MD-PhD Professor Departments of Pathology and Medicine (Oncology) Director, Yale Pathology Tissue Services Disclosures
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More informationReceptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
Montor et al. Molecular Cancer (2018) 17:55 https://doi.org/10.1186/s12943-018-0792-2 REVIEW Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationPersonalised Healthcare. will it deliver? Bob Holland Head of Personalised Healthcare & Biomarkers Innovative Medicines AstraZeneca R&D
Personalised Healthcare x will it deliver? Bob Holland Head of Personalised Healthcare & Biomarkers Innovative Medicines AstraZeneca R&D Personalised Healthcare It is delivering! Bob Holland Head of Personalised
More informationBreast Cancer Targeting: Hippo, a pathway too big to hide. Stuart Aaronson, M.D. Icahn School of Medicine at Mount Sinai
Breast Cancer Targeting: Hippo, a pathway too big to hide Stuart Aaronson, M.D. Icahn School of Medicine at Mount Sinai DISCLOSURES I am a consultant for Aileron Therapeutics, Inc. and R-Pharm. Outline:
More informationLondon Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
More informationMonoclonal Antibodies & Tyrosine-Kinase Inhibitors
Monoclonal Antibodies & Tyrosine-Kinase Inhibitors Charlotte Capstick Clinical Pharmacist Oncology Weston Park Hospital Sheffield Teaching Hospitals NHS Trust Contents Background Dosing Renal impairment
More informationRegorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer
News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com Regorafenib from Bayer Submitted
More informationClinical Colon Cancer Abby Siegel MD COLON CANCER. 1. Epidemiology 2. Risk factors 3. Manifestations 4. Treatment
Clinical Colon Cancer 2008 Abby Siegel MD COLON CANCER 1. Epidemiology 2. Risk factors 3. Manifestations 4. Treatment 1 1. EPIDEMIOLOGY - Colorectal cancer is the third most common cancer in the United
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationThe linking of specific cancer genetic alterations to molecular targeted therapies is driving a new era of personalised medicine
The linking of specific cancer genetic alterations to molecular targeted therapies is driving a new era of personalised medicine Oncologica addresses this new era of precision medicine by exploiting state
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationGenetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School
Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW
More informationIntegrating Clinical Genomics and Cancer Care. Maria Blazo, M.D. Division Director, Clinical Genetics September 9, 2017
Integrating Clinical Genomics and Cancer Care Maria Blazo, M.D. Division Director, Clinical Genetics September 9, 2017 Precision Medicine Initiative Genomic and Precision Medicine: The Future is Now 1
More informationADVANCES IN COLON CANCER
ADVANCES IN COLON CANCER Peter T. Silberstein, M.D., FACP Professor, Creighton University Chief Hematology/Oncology UNIVERSAL SCREENING FOR LYNCH SYNDROME OF ALL PATIENTS WITH COLON CANCER ADOPTED BY CHI
More informationAzacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
More informationTargets & therapies for colorectal cancer
Targets & therapies for colorectal cancer Jan Schellens Werkgroep "MOLECULAIRE DIAGNOSTIEK IN DE PATHOLOGIE 31-01-2014 Current treatment options for advanced colorectal cancer (CRC) First line: - CAPOX
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationA View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.
A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How
More informationCyramza. Cyramza (ramucirumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.44 Subject: Cyramza Page: 1 of 6 Last Review Date: June 24, 2016 Cyramza Description Cyramza (ramucirumab)
More informationPersonalized Medicine in Oncology Ethical Implications for Supportive Care
Personalized Medicine in Oncology Ethical Implications for Supportive Care Dr. Béatrice Godard Professeur Titulaire École de santé publique Département de médecine sociale et préventive Université de Montréal
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationThemes. Evaluer (defini:on, diagnos:c criteria) Recherche clinique en cancérologie : quid du statut nutri:onnel? Agir Adapter 03/04/15
Recherche clinique en cancérologie : quid du statut nutri:onnel? Pierre Senesse, Laboratoire Epsylon, Ins:tut Régional du Cancer de Montpellier SIRIC Vickie Baracos, Department of Oncology, University
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Stivarga) Reference Number: CP.CPA.157 Effective Date: 11.16.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationCABOMETYX (cabozantinib) oral tablet
CABOMETYX (cabozantinib) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationTargeted Therapy Vijay Narang
25 Volume 1, Issue 1, January 2013, Online: Targeted Therapy Vijay Narang ABSTRACT This is a review on targeted therapy that blocks the growth and spread of cancer by interfering with specific molecules
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationA Clinical Context Report
Non-small Cell Lung Cancer in Practice An Expert Commentary With Karen Reckamp, MD A Clinical Context Report Clinical Context: NSCLC in Practice Expert Commentary Jointly Sponsored by: and Clinical Context:
More information